Previous studies show that
astragaloside IV (ASIV) has anti-renal
fibrosis effects. However, its mechanism remains elusive. In this study, we investigated the anti-
fibrosis mechanisms of ASIV on
chronic kidney disease (CKD) in vivo and in vitro. A CKD model was induced in rats with
adenine (200 mg/kg/d, i.g.), and an in vitro renal
fibrosis model was induced in human kidney-2 (HK-2) cells treated with TGF-β1. We revealed that ASIV significantly alleviated renal
fibrosis by suppressing the expressions of epithelial-mesenchymal transition (EMT)-related
proteins, including
fibronectin,
vimentin, and alpha-smooth muscle actin (α-SMA), and G2/M arrest-related
proteins, including phosphorylated p53 (p-p53), p21, phosphorylated
histone H3 (p-H3), and Ki67 in both of the in vivo and in vitro models. Transcriptomic analysis and subsequent validation showed that ASIV rescued ALDH2 expression and inhibited AKT/mTOR-mediated autophagy. Furthermore, in ALDH2-knockdown HK-2 cells, ASIV failed to inhibit AKT/mTOR-mediated autophagy and could not blunt EMT and G2/M arrest. In addition, we further demonstrated that
rapamycin, an autophagy inducer, reversed the treatment of ASIV by promoting autophagy in TGF-β1-treated HK-2 cells. A dual-
luciferase report assay indicated that ASIV enhanced the transcriptional activity of the ALDH2 promoter. In addition, a further molecular docking analysis showed the potential interaction of ALDH2 and ASIV. Collectively, our data indicate that ALDH2-mediated autophagy may be a novel target in treating renal
fibrosis in CKD models, and ASIV may be an effective targeted
drug for ALDH2, which illuminate a new insight into the treatment of renal
fibrosis and provide new evidence of pharmacology to elucidate the anti-
fibrosis mechanism of ASIV in treating renal
fibrosis.